EN DE
STOCK COMPARISON

CHOSA Oncology AB vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our 21 valuation models. Here is how CHOSA Oncology AB (CHOSA) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 2, 2026.

As of Aug 2, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: CHOSA Oncology AB trades at SEK 0.83 versus a fair value of SEK 0.12 (-85%), while Vertex Pharmaceuticals trades at $477 versus $279 (-42%).
CHOSA Oncology AB
CHOSA.ST · SEK · Healthcare
-85%
above fair value
overvalued
PriceSEK 0.83
Fair ValueSEK 0.12
Quality32/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-42%
above fair value
overvalued
Price$477
Fair Value$279
Quality73/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

CHOSA Oncology ABVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
1.73×P/S (TTM)10.06×
0.48×P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
Profitability
-123%Net margin36%
—Operating margin38%
-34%Return on equity24%
-23%Return on assets12%
Growth
0%Revenue growth (YoY)8%
—Avg. growth/yr (3Y)10.6%
—Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$8MMarket cap$123B
—Growth qualityhealthy

Vertex Pharmaceuticals leads: 2 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

CHOSA Oncology ABof which business quality 27 · market factors 47 Vertex Pharmaceuticalsof which business quality 77 · market factors 57
ProfitabilityMargins and returns on capital today
0
72
Quality GrowthAre margins and returns improving?
25
65
CashflowEarnings quality: real cash, not paper profit
15
79
Fin. StrengthBalance sheet, leverage, solvency risk
77
92
InvestmentDisciplined investing over empire-building
20
58
Low VolatilityCalm price path (market factor)
50
76
MomentumPrice trend over the last 3–12 months (market factor)
46
48
52W MomentumDistance to the 52-week high (market factor)
47
51
Net IssuanceBuybacks instead of dilution
19
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

CHOSA Oncology AB

Asset-BasedSEK 0.12

1 of 1 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$429
Earnings-Based$516
Dividend Discount$7.07
Multiples$246
Asset-Based$49.27
Growth DCF$333
Economic Profit$254
Growth Earnings$672

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

CHOSA Oncology AB
Bear SEK 0.09Fair Value SEK 0.12Bull SEK 0.18
SEK 0.83 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$477 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

CHOSA Oncology AB · Healthcare

Quality score32 · bottom 25%
Fair value upside-85% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score73 · Top 25%
Fair value upside-42% · below median

Bottom line

As of Aug 2, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: CHOSA Oncology AB trades at SEK 0.83 versus a fair value of SEK 0.12 (-85%), while Vertex Pharmaceuticals trades at $477 versus $279 (-42%).

Vertex Pharmaceuticals has the higher quality score (73/100).

See the full analysis →
CHOSA Oncology AB · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to CHOSA Oncology AB

Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs Toyota Motor Corporation

Related to Vertex Pharmaceuticals

Amazon.com vs PDD HoldingsAmazon.com vs Sony GroupMeta Platforms vs Verizon CommunicationsMeta Platforms vs At&t
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.